CAPS and NLRP3.
Booshehri LM, Hoffman HM.
J Clin Immunol. 2019 Apr;39(3):277-286. doi: 10.1007/s10875-019-00638-z. Epub 2019 May 10.
Periodic fever syndromes.
Lachmann HJ.
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):596-609. doi: 10.1016/j.berh.2017.12.001. Epub 2018 Jan 11.
Cold urticaria.
Lin RY, Janniger CK, Schwartz RA, Lambert WC.
Am Fam Physician. 1986 Feb;33(2):145-50.
Systemic autoinflammatory diseases: Clinical state of the art.
Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V.
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101529. doi: 10.1016/j.berh.2020.101529. Epub 2020 Jun 13.
[Cold-induced urticaria].
Delorme N, Drouet M, Thibaudeau A, Verret JL.
Allerg Immunol (Paris). 2002 Sep;34(7):255-8.
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors.
Zhan X, Li Q, Xu G, Xiao X, Bai Z.
Front Immunol. 2023 Jan 18;13:1109938. doi: 10.3389/fimmu.2022.1109938. eCollection 2022.
Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production.
Sanchez-Lopez E, Zhong Z, Stubelius A, Sweeney SR, Booshehri LM, Antonucci L, Liu-Bryan R, Lodi A, Terkeltaub R, Lacal JC, Murphy AN, Hoffman HM, Tiziani S, Guma M, Karin M.
Cell Metab. 2019 Jun 4;29(6):1350-1362.e7. doi: 10.1016/j.cmet.2019.03.011. Epub 2019 Apr 11.
Cold Urticaria Triggered After Treatment With Amoxicillin-Clavulanic Acid.
García-Paz V, Romero-Sánchez L, Otero-Alonso A, González-Rivas M, Fernández-Franco I, Vila Sexto L.
J Investig Allergol Clin Immunol. 2023 Dec 14;33(6):495-497. doi: 10.18176/jiaci.0907. Epub 2023 Apr 12.
Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.
Bréhon A, Bensefa-Colas L, D'Andrea C, Jeziorski E, Lehucher-Michel MP, Lequipe J, Marmion N, Mathelier-Fusade P, Mercier JC, Sebatigita G, Tannous J, Vigan M, Guillot B, Du-Thanh A, Soria A.
Br J Dermatol. 2024 Feb 16;190(3):445-447. doi: 10.1093/bjd/ljad447.
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, Benseler S, Berard R, Broderick L, Dedeoglu F, Diebold M, Durrant KL, Ferguson P, Foell D, Hausmann J, Jones OY, Kastner DL, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman H, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E.
Ann Rheum Dis. 2022 Jul;81(7):907-921. doi: 10.1136/annrheumdis-2021-221801. Epub 2022 May 27.
